JP2024531682A5 - - Google Patents

Info

Publication number
JP2024531682A5
JP2024531682A5 JP2024515828A JP2024515828A JP2024531682A5 JP 2024531682 A5 JP2024531682 A5 JP 2024531682A5 JP 2024515828 A JP2024515828 A JP 2024515828A JP 2024515828 A JP2024515828 A JP 2024515828A JP 2024531682 A5 JP2024531682 A5 JP 2024531682A5
Authority
JP
Japan
Prior art keywords
positive
cell population
inhibitor
committed
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024515828A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024531682A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/076328 external-priority patent/WO2023039588A1/en
Publication of JP2024531682A publication Critical patent/JP2024531682A/ja
Publication of JP2024531682A5 publication Critical patent/JP2024531682A5/ja
Pending legal-status Critical Current

Links

JP2024515828A 2021-09-13 2022-09-13 コミットされた心臓始原細胞の製造方法 Pending JP2024531682A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163243606P 2021-09-13 2021-09-13
US63/243,606 2021-09-13
PCT/US2022/076328 WO2023039588A1 (en) 2021-09-13 2022-09-13 Methods for the production of committed cardiac progenitor cells

Publications (2)

Publication Number Publication Date
JP2024531682A JP2024531682A (ja) 2024-08-29
JP2024531682A5 true JP2024531682A5 (cg-RX-API-DMAC7.html) 2025-09-12

Family

ID=83508810

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024515828A Pending JP2024531682A (ja) 2021-09-13 2022-09-13 コミットされた心臓始原細胞の製造方法

Country Status (8)

Country Link
US (1) US20230078230A1 (cg-RX-API-DMAC7.html)
EP (1) EP4402249A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024531682A (cg-RX-API-DMAC7.html)
KR (1) KR20240056604A (cg-RX-API-DMAC7.html)
CN (1) CN118159646A (cg-RX-API-DMAC7.html)
AU (1) AU2022343749A1 (cg-RX-API-DMAC7.html)
CA (1) CA3231501A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023039588A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025117472A1 (en) * 2023-11-30 2025-06-05 Immorta Bio, Inc. Treatment of heart failure using pluripotent stem cell derived cardiomyocytes and derivatives thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2197915B (en) 1986-11-19 1990-11-14 Rolls Royce Plc Improvements in or relating to fluid bearings
US6416998B1 (en) 1992-09-02 2002-07-09 Baylor College Of Medicine Plasmid encoding a modified steroid hormone
US5874301A (en) 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5763270A (en) 1995-06-07 1998-06-09 Genemedicine, Inc. Plasmid for delivery of nucleic acids to cells and methods of use
JP2001508302A (ja) 1997-01-10 2001-06-26 ライフ テクノロジーズ，インコーポレイテッド 胚性幹細胞血清置換
US6099832A (en) 1997-05-28 2000-08-08 Genzyme Corporation Transplants for myocardial scars
US6280718B1 (en) 1999-11-08 2001-08-28 Wisconsin Alumni Reasearch Foundation Hematopoietic differentiation of human pluripotent embryonic stem cells
AU3929402A (en) 2000-11-22 2002-06-11 Geron Corp Tolerizing allografts of pluripotent stem cells
PE20020958A1 (es) 2001-03-23 2002-11-14 Bayer Corp Inhibidores de la rho-quinasa
HN2002000067A (es) 2001-03-23 2003-10-24 Bayer Healthcare Llc Inhibidores de la rho - quinasa.
US20030211603A1 (en) 2001-08-14 2003-11-13 Earp David J. Reprogramming cells for enhanced differentiation capacity using pluripotent stem cells
CN1630716A (zh) 2001-12-07 2005-06-22 杰龙公司 人胚胎干细胞衍生的造血细胞
EP1465900B1 (en) 2002-01-10 2008-05-14 Bayer HealthCare AG Rho-kinase inhibitors
CA2473910C (en) 2002-01-23 2011-03-15 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
MXPA04007191A (es) 2002-01-23 2005-03-31 Bayer Pharmaceuticals Corp Derivados de pirimidina como inhibidores de rho-quinasa.
WO2004028563A1 (en) 2002-09-27 2004-04-08 Genexine Inc. A vaccine enhancing the protective immunity to hepatitis c virus using plasmid dna and recombinant adenovirus
ES2273047T3 (es) 2002-10-28 2007-05-01 Bayer Healthcare Ag Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa.
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
JP5141016B2 (ja) 2004-06-18 2013-02-13 独立行政法人理化学研究所 無血清浮遊培養による胚性幹細胞の神経分化誘導法
BRPI0514641A (pt) 2004-09-08 2008-06-17 Wisconsin Alumni Res Found cultivação das células tronco embriÈnica humana
EP1951751B1 (en) 2005-11-14 2017-11-01 Merial, Inc. Gene therapy for renal failure
US20070116680A1 (en) 2005-11-18 2007-05-24 Rensselaer Polytechnic Institute Stem cells within gel microenvironments
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
EP2206724A1 (en) 2005-12-13 2010-07-14 Kyoto University Nuclear reprogramming factor
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
DK3399025T3 (da) 2007-03-23 2025-06-16 Wisconsin Alumni Res Found Omprogrammering af somatiske celler
US9683232B2 (en) 2007-12-10 2017-06-20 Kyoto University Efficient method for nuclear reprogramming
ES2587395T3 (es) 2008-06-04 2016-10-24 Cellular Dynamics International, Inc. Procedimientos para la producción de células IPS usando un enfoque no vírico
EP2318520B1 (en) * 2008-07-25 2017-10-11 The University Of Georgia Research Foundation, Inc. Compositions for mesoderm derived isl1+ multipotent cells (imps), epicardial progenitor cells (epcs) and multipotent cxcr4+cd56+ cells (c56cs) and methods of use
WO2010019569A1 (en) 2008-08-12 2010-02-18 Cellular Dynamics International. Inc. Methods for the production of ips cells
EP3450545B1 (en) 2008-10-24 2023-08-23 Wisconsin Alumni Research Foundation Pluripotent stem cells obtained by non-viral reprogramming
CN105925535A (zh) 2009-06-05 2016-09-07 细胞动力国际有限公司 重编程t细胞和造血细胞的方法
US8900871B2 (en) 2009-08-07 2014-12-02 Kyoto University Method of producing induced pluripotent stem cells using inhibitors of P53
EP3255142A1 (en) 2009-10-19 2017-12-13 Cellular Dynamics International, Inc. Cardiomyocyte production
KR101775926B1 (ko) 2009-11-04 2017-09-07 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 화학 물질을 이용한 에피솜 재프로그래밍
US9005967B2 (en) 2010-01-22 2015-04-14 Kyoto University Myc variants improve induced pluripotent stem cell generation efficiency
CA2802249A1 (en) 2010-06-15 2011-12-22 Cellular Dynamics International, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood
WO2013184527A1 (en) * 2012-06-05 2013-12-12 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
WO2014104364A1 (ja) * 2012-12-28 2014-07-03 国立大学法人京都大学 人工多能性幹細胞、心筋細胞又はその前駆細胞の製造方法
WO2016029122A1 (en) * 2014-08-22 2016-02-25 Chien Kenneth R Use of jagged 1/frizzled 4 as a cell surface marker for isolating human cardiac ventricular progenitor cells
US9765299B2 (en) * 2014-09-10 2017-09-19 Wisconsin Alumni Research Foundation Chemically defined albumin-free conditions for cardiomyocyte differentiation of human pluripotent stem cells
AU2019305585A1 (en) * 2018-07-17 2021-01-28 The Regents Of The University Of California Cells differentiated from immunoengineered pluripotent cells

Similar Documents

Publication Publication Date Title
Vats et al. Chondrogenic differentiation of human embryonic stem cells: the effect of the micro-environment
US20250295701A1 (en) Kit for Induction of Continuous Expansion of Hepatoblast Organoids and/or Hepatocyte Organoids Under 3D Suspension Conditions and Use Thereof
Levenberg Engineering blood vessels from stem cells: recent advances and applications
Montserrat et al. Regenerative strategies for kidney engineering
Pagliarosi et al. Building an artificial cardiac microenvironment: a focus on the extracellular matrix
JPWO2019107535A1 (ja) 多能性幹細胞からの立体臓器の構築
CN113699098A (zh) 三维血管化心肌组织及其制备方法和应用
CN113337458A (zh) 一种提高多能干细胞定向诱导心肌细胞产量及纯度的方法
Pagliari et al. A multistep procedure to prepare pre-vascularized cardiac tissue constructs using adult stem sells, dynamic cell cultures, and porous scaffolds
Hanjaya‐Putra et al. Vascular engineering using human embryonic stem cells
CN111909887A (zh) 获得肝脏细胞的方法和组合物
US9428735B2 (en) Smooth muscle-like cells (SMLCs) dervided from human pluripotent stem cells
WO2023106122A1 (ja) 間葉系譜への分化に特化した神経堤細胞の製造方法
CN105647860A (zh) 临床治疗级人胎盘底蜕膜来源的间充质干细胞(PDB-MSCs)无血清体外提取制备方法
JP7094567B2 (ja) 神経堤細胞および交感神経細胞の製造方法
CN115786245A (zh) 人仿生肺脏类器官构建方法
KR20230143136A (ko) 자가 조직화된 인간 심장 오가노이드
JP2023536421A (ja) 多能性幹細胞由来細胞の大規模製造のための閉鎖型製造プロセス
CN117384824A (zh) 基于iPSC的人血管化肺类器官及其构建方法
CN119570719A (zh) 一种心脏类器官及其体外制备方法
CN120158421A (zh) 一种共分化的血管化肝类器官及其构建方法
EP2872620A1 (en) Derivation and self-renewal of isi1+ cells and uses thereof
Luo et al. The efficiency of stem cell differentiation into functional beta cells for treating insulin-requiring diabetes: recent advances and current challenges
Zhu et al. Ex vivo expansion of adipose tissue‐derived stem cells in spinner flasks
CN115772492B (zh) 利用博来霉素体外构建肺纤维化疾病模型的方法